Duobrii vs. Skyrizi

• Are Duobrii and Skyrizi the Same Thing?
• What Are Possible Side Effects of Duobrii?
• What Are Possible Side Effects of Skyrizi?
• What Is Duobrii?
• What Is Skyrizi?
• What Drugs Interact with Duobrii?
• What Drugs Interact with Skyrizi?
• How Should Duobrii Be Taken?
• How Should Skyrizi Be Taken?

Duobrii (halobetasol propionate and tazarotene) Lotion and Skyrizi (risankizumab-rzaa) are used to treat plaque psoriasis in adults.

Duobrii Lotion is a topical (for the skin) treatment and Skyrizi is given as a subcutaneous injection.

Duobrii and Skyrizi belong to different drug classes. Duobrii is a combination of a corticosteroid and a retinoid and Skyrizi is an interleukin-23 antagonist.

Side effects of Duobrii that are different from Skyrizi include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, rash, stretch marks, and skin peeling.

Side effects of Skyrizi that are different from Duobrii include upper respiratory infections, headache, fatigue, injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and tinea infections (such as ringworm, athlete's foot and jock itch)

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Skyrizi may interact with "live" vaccines.

Common side effects of Duobrii include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Common side effects of Skyrizi include:

• upper respiratory infections,
• headache,
• fatigue,
• injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
• tinea infections (such as ringworm, athlete's foot and jock itch)

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.